WO2017064564A3 - Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody - Google Patents

Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody Download PDF

Info

Publication number
WO2017064564A3
WO2017064564A3 PCT/IB2016/001600 IB2016001600W WO2017064564A3 WO 2017064564 A3 WO2017064564 A3 WO 2017064564A3 IB 2016001600 W IB2016001600 W IB 2016001600W WO 2017064564 A3 WO2017064564 A3 WO 2017064564A3
Authority
WO
WIPO (PCT)
Prior art keywords
psoriatic arthritis
therapeutic regimens
ccl20 antibody
treating psoriatic
ccl20
Prior art date
Application number
PCT/IB2016/001600
Other languages
French (fr)
Other versions
WO2017064564A2 (en
Inventor
Michael James HERDMAN
Stefano ZAMUNER
Ruth Margaret TARZI
Leigh Michael FELTON
Original Assignee
Glaxosmithkline Intellectual Property Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Limited filed Critical Glaxosmithkline Intellectual Property Limited
Publication of WO2017064564A2 publication Critical patent/WO2017064564A2/en
Publication of WO2017064564A3 publication Critical patent/WO2017064564A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides therapeutic regimens for inflammatory conditions (e.g psoriatic arthritis, Behcet's disease, and inflammatory bowel diseases such as ulcerative colitis and Crohn's disease) using anti-CCL20 antibodies, and uses antibodies for preparation of medicaments for the inflammatory conditions.
PCT/IB2016/001600 2015-10-16 2016-10-14 Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody WO2017064564A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562242975P 2015-10-16 2015-10-16
US62/242,975 2015-10-16

Publications (2)

Publication Number Publication Date
WO2017064564A2 WO2017064564A2 (en) 2017-04-20
WO2017064564A3 true WO2017064564A3 (en) 2017-06-08

Family

ID=57570572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/001600 WO2017064564A2 (en) 2015-10-16 2016-10-14 Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody

Country Status (1)

Country Link
WO (1) WO2017064564A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068540A2 (en) * 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068540A2 (en) * 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis - Full Text View - ClinicalTrials.gov", CLINICALTRIALS.GOV, 18 January 2016 (2016-01-18), XP055353643, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT02671188> [retrieved on 20170310] *
ANONYMOUS: "Single Dose Escalation Trial to Evaluate the Safety, Tolerability PharmacokinFull Text View - Clinetics and Pharmacodynamics of GSK3050002 - NCT01984047", CLINICALTRIALS.GOV, 1 March 2015 (2015-03-01), XP055353085, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT01984047> [retrieved on 20170309] *
LAURA J. SAVAGE ET AL: "Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis", RHEUMATOLOGY AND THERAPY, vol. 2, no. 1, 17 March 2015 (2015-03-17), pages 1 - 16, XP055353607, ISSN: 2198-6576, DOI: 10.1007/s40744-015-0010-2 *
RAQUEL CELIS ET AL: "Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 14, no. 2, 27 April 2012 (2012-04-27), pages R93, XP021125971, ISSN: 1478-6354, DOI: 10.1186/AR3817 *

Also Published As

Publication number Publication date
WO2017064564A2 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
WO2016191643A3 (en) Tigit-binding agents and uses thereof
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
WO2018089508A3 (en) Anti-cd47 antibodies
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
WO2017077085A3 (en) Immunomodulatory antibodies
WO2017030823A3 (en) Anti-tigit antibodies
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
SG10201803042PA (en) Anti-tim-3 antibodies
WO2016149710A3 (en) Hiv-1 neutralizing antibodies and uses thereof
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
WO2015173633A3 (en) Hdl therapy markers
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
WO2015164392A8 (en) Novel anti-rnf43 antibodies and methods of use
WO2017049038A3 (en) Anti-cd115 antibodies
PH12016501366A1 (en) Novel anti-baff antibodies
EP3411504A4 (en) Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2017181079A3 (en) Methods for monitoring and treating cancer
MX2022010809A (en) Methods for diagnosing and treating inflammatory bowel disease.
WO2017214170A3 (en) Baff-r antibodies and uses thereof
IL268007A (en) Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
EA201890747A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
WO2016154623A3 (en) Anti-cd133 monoclonal antibodies and related compositions and methods
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
EP3500293A4 (en) Methods of treating crohn&#39;s disease with an anti-nkg2d antibody

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16813244

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16813244

Country of ref document: EP

Kind code of ref document: A2